NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

That is a solid read. The key change is that once NWBO acquired Advent, the sponsor and the manufacturer became the same entity. Under SI 2025/87, that alignment allows Eden validation to be folded into the live MAA rather than pushed out as a Type II variation.

Without the acquisition, MHRA would almost certainly have required a sequential approval path: first the manual process, then a 60 to 90 day variation cycle to add Eden. By owning Advent, NWBO avoided that two step process. The MAA can now be reviewed as a single dossier with Eden embedded, one decision rather than two.

So yes, if MHRA accepted that amended filing after SI 87 came into force, we are simply waiting for the comprehensive decision. That is what collapses the regulatory clock and explains why the review has taken a little longer.

🧬 The Acquisition That Collapsed the Clock: How $NWBO Owning Advent Let Eden Into the Dossier Without Delay

TLDR

By buying Advent, $NWBO avoided months of extra red tape. Without the deal, Eden would have triggered a “Type II variation” — a regulatory change that forces a new… https://t.co/EeDNG06bku

— Andrew Caravello, DO (@andrewcaravello) September 5, 2025